更新于：2024-12-27
Levetiracetam
左乙拉西坦
更新于：2024-12-27
概要
基本信息
简介左乙拉西坦 (Levetiracetam) 是一种小型分子实体，已被设计用于将突触小泡蛋白 2A (SV2A) 作为调节靶标。这种药物化合物是 UCB SA 辛勤努力的成果，并于 1999 年 11 月获得首次批准。在医学领域，左乙拉西坦被广泛用作治疗癫痫的抗惊厥药。已知该化合物通过减少患者癫痫发作的频率和强度而表现出抗惊厥特性。 Levetiracetam 的调节作用源于它与 SV2A 蛋白的结合，SV2A 蛋白在大脑中神经递质释放的调节中发挥作用。此外，该化合物良好的副作用特征及其对患者的显着耐受性使其成为癫痫治疗的常用选择。 |
药物类型 小分子化药 |
别名 Levetiracetam (JAN/USP/INN)、Levetiracetame、AGB-101 + [22] |
靶点 |
作用机制 SV2A调节剂(突触囊泡蛋白2A调节剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-11-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构
分子式C8H14N2O2 |
InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N |
CAS号102767-28-2 |
关联
431
项与 左乙拉西坦 相关的临床试验Pilot Study: Levetiracetam Prophylaxis Randomized Controlled Trial in Brain Tumor Resection
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101 on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease in Apolipoprotein E4 Non-carriers
A Randomized Controlled Trial Comparing the Prevention of Febrile Seizures in Children with Intermittent Oral Levetiracetam for Two weeks Versus Clobazam - NIL
100 项与 左乙拉西坦 相关的临床结果
登录后查看更多信息
100 项与 左乙拉西坦 相关的转化医学
登录后查看更多信息
100 项与 左乙拉西坦 相关的专利（医药）
登录后查看更多信息
5,483
项与 左乙拉西坦 相关的文献（医药）2025-02-01BRAIN & DEVELOPMENT
Levetiracetam for pediatric migraine prophylaxis: A narrative review
Review
作者: Shafaei-Bajestani, Negar ; Shahrokhi, Maryam ; Mashayekhi-sardoo, Habibeh ; Pur, Amir Mohammad Davari Fard ; Mashayekhi-Sardoo, Habibeh
BACKGROUND:
Migraine, a common primary headache disorder, affects children and adolescents under 18, often bilateral and lasting 2-72 hours, affecting 7.7% of them.
OBJECTIVE:
Recent studies on migraine prevention and treatment in children and adolescents have explored the potential benefits of levetiracetam, considering its side effects and potential effects on migraines. Hence, we aimed to review the studies that have examined the possible mechanism and beneficial effects of levetiracetam in children's and adolescents' migraine.
METHODS:
A comprehensive search of English and non-English trials evaluating levetiracetam's effectiveness in pediatric migraine treatment using relevant keywords was conducted in scientific databases including PubMed, Web of Science, and the Cochrane Controlled Trials Register in Feb 2024. The studies included non-randomized controlled trials, uncontrolled trials, and retrospectively reviewed medical charts plus randomized controlled trials.
RESULTS:
Seven studies were included in this review. They revealed that levetiracetam can promisingly complete the resolution of migraines, and decrease the duration, severity, number of migraine episodes, and frequency of migraine in children. In addition, levetiracetam diminished the Pediatric Migraine Disability Assessment Scale score in them.
CONCLUSION:
Seven studies suggest levetiracetam, at doses ranging from 20 to 60 mg/kg/day (250-3000 mg/day), can significantly reduce migraine frequency and duration, but larger controlled trials are needed.
2025-02-01JOURNAL OF PHARMACY PRACTICE
The Phenytoin Ataxia Enigma Unveiled “A Case Report’’
Article
作者: Patel, Nishi ; Premal, Yatvi ; Khadela, Avinash ; Sadhwani, Devang ; Dave, Bhavarth
Background: Phenytoin (PHT) has been approved for the treatment of epilepsy. It belongs to the category of medications with a limited therapeutic window and requires therapeutic drug monitoring (TDM). PTH has been observed to induce a variety of Adverse drug reactions (ADRs) including ataxia, dystonia, nystagmus, dyskinesia, etc. Phenytoin-induced ataxia is an uncommonly observed ADR of Phenytoin whose reports are extremely limited. Case: Herein, we present a case report of a 16-year-old Asian patient with a past history of epilepsy that was admitted to a tertiary care hospital due to the development of ataxia, giddiness, and vomiting when taking Phenytoin in addition to Oxcarbazepine, Clobazam, and Levetiracetam to treat seizures. On admission, Magnetic resonance imaging (MRI) findings revealed bilateral variable cerebrospinal fluid (CSF) lesions in the parieto-occipital region of the periventricular area (periventricular leukomalacia). Additionally, serum Phenytoin levels were observed to be in the toxic range (40 μg/mL) due to which physicians confirmed the ADR to be due to Phenytoin toxicity. Thus, the Phenytoin drug was discontinued in the patient gradually and he was continued on clobazam, oxcarbazepine, and brivaracetam which led to reversal of the ADR in the patient. Conclusion: In this case, ataxia resulted from Phenytoin overdose, as confirmed by MRI and serum tests suggesting that TDM of Phenytoin is essential to prevent ADRs. Given the scarcity of ataxia cases caused by Phenytoin, awareness is lacking within the scientific community. Our aim is to provide insights to promote better monitoring and patient-centered treatment outcomes for epileptic patients.
2025-02-01EPILEPSY & BEHAVIOR
Effect of antiepileptic drug monotherapy on endogenous sex hormonal profile in men and women with epilepsy
Article
作者: Kukreti, Shrikant ; Singh, Priyanka ; Thakran, Sarita ; Panda, Biswajit ; Sardana, Viren ; Kukal, Samiksha ; Kanojia, Neha ; Thakur, Jyotika ; Guin, Debleena ; Grover, Sandeep ; Srivastava, Ankit ; Machahary, Nitin ; Kukreti, Ritushree ; Singh, Anju ; Singh, Pooja ; Saso, Luciano
OBJECTIVE:
To assess the alterations of endogenous sex hormone profiles in patients with epilepsy (PWE) on different antiepileptic drug (AED) monotherapies compared to healthy controls and drug naïve PWE (DNPWE).
METHODS:
Four databases MEDLINE, EMBASE, SCOPUS, and CENTRAL were searched for analytical observational/intervention studies on the assessment of endogenous sex hormones in PWE compared to healthy controls and DNPWE. Two researchers reviewed the title/abstract, and full-text articles for the selection of the studies independently. Extracted data included information on study details, participant demographics, interventions, method of assessment and study results. The study outcomes were used to calculate the standard mean differences (SMD) and 95% confidence interval (CI) as effect size for assessing differences in the endogenous sex hormone levels between the treatment group and control/DNPWE.
RESULTS:
Among 5888 publications retrieved, 33 studies were included. Enzyme-inducing AEDs (EIAEDs) such as phenytoin (men: SMD = 1.36; 95%CI = 1.06,1.66) and carbamazepine (men: SMD = 0.71; 95%CI = 0.39, 1.04 and women: SMD = 0.54; 95%CI = 0.25, 0.83) and weak-EIAED oxcarbazepine (men: SMD = 0.62; 95%CI = 0.26,0.99) increased the SHBG levels in PWE compared to control. The same trend was observed when comparing it to DNPWE. No significant changes in SHBG were observed for non-EIAEDs valproic acid, lamotrigine and levetiracetam in men. Lamotrigine significantly reduced SHBG in women (SMD = -0.50; 95%CI = -0.85, -0.16) compared to controls. Testosterone (T) levels were significantly reduced for both carbamazepine (SMD = -0.39; 95%CI = -0.67, -0.11) and valproic acid (SMD = -0.48; 95%CI = -0.74, -0.21) treated men compared to control.
SIGNIFICANCE:
Our findings emphasize the importance of screening the endogenous sex hormonal profile in PWE on AED monotherapies to evaluate the associated endocrine-related perturbations which may impact reproductive functions.
100 项与 左乙拉西坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 部分性癫痫持续状态 | 日本 | 2023-06-26 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫发作 | 澳大利亚 | 2006-09-07 | |
| Dravet综合征 | 欧盟 | 2000-09-29 | |
| Dravet综合征 | 冰岛 | 2000-09-29 | |
| Dravet综合征 | 列支敦士登 | 2000-09-29 | |
| Dravet综合征 | 挪威 | 2000-09-29 | |
| 特发全身性癫痫 | 欧盟 | 2000-09-29 | |
| 特发全身性癫痫 | 冰岛 | 2000-09-29 | |
| 特发全身性癫痫 | 列支敦士登 | 2000-09-29 | |
| 特发全身性癫痫 | 挪威 | 2000-09-29 | |
| 强直阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 强直阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 强直阵挛性癫痫 | 挪威 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 挪威 | 2000-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2018-12-13 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 美国 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 加拿大 | 2018-12-13 | |
| 继发性全身性癫痫发作 | 临床3期 | 中国 | 2010-10-01 | |
| 继发性全身性癫痫发作 | 临床3期 | 日本 | 2010-10-01 | |
| 创伤性脑损伤 | 临床3期 | 法国 | 2007-11-01 | |
| 外伤后癫痫 | 临床3期 | 法国 | 2007-11-01 | |
| 创伤后癫痫 | 临床3期 | 法国 | 2007-11-01 | |
| 酗酒 | 临床3期 | 德国 | - | 2007-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 82 | (Levetiracetam) | 構鹽艱齋壓膚範簾醖製(鬱顧醖繭鹽鹹衊淵衊選) = 簾鏇構鏇鑰餘憲夢餘觸 餘鹽顧選獵範壓獵構願 (襯憲獵簾鏇淵選窪願築, 廠範襯廠願觸獵衊獵窪 ~ 衊夢願糧鹽鏇鬱廠構觸) 更多 | - | 2024-11-29 | ||
(No Levetiracetam) | 構鹽艱齋壓膚範簾醖製(鬱顧醖繭鹽鹹衊淵衊選) = 蓋壓窪壓窪憲選簾蓋鏇 餘鹽顧選獵範壓獵構願 (襯憲獵簾鏇淵選窪願築, 築壓繭鏇餘鑰製蓋積糧 ~ 窪窪繭鏇願夢選衊襯膚) 更多 | ||||||
临床3期 | 38 | (Levetiracetam: Adjunctive Therapy) | 遞鹽觸糧觸顧製醖壓壓(淵齋鑰糧鑰範積衊廠襯) = 簾製積鏇願襯願顧夢膚 鑰糧觸衊蓋膚獵繭窪壓 (襯構壓構膚窪觸醖淵艱, 夢夢齋製糧製膚窪餘鬱 ~ 網積鏇構鹽鬱憲夢範夢) 更多 | - | 2024-07-23 | ||
(Levetiracetam: Monotherapy) | 憲醖繭淵鬱網膚鹹構簾(醖鬱選糧廠鹽餘餘糧壓) = 願網遞網鏇夢窪願觸顧 襯構遞鬱築膚鏇醖餘繭 (簾餘窪製憲製構糧構積, 餘糧襯艱鏇網願窪淵襯 ~ 選齋齋膚淵窪窪壓蓋蓋) 更多 | ||||||
临床2/3期 | 164 | Placebo Oral Tablet (Placebo Oral Tablet) | 選願顧網構鏇醖艱襯構(鏇鬱網積繭繭糧鏇鹽顧) = 夢餘鬱範壓範構廠積顧 齋選壓窪鬱繭築齋壓衊 (鹹淵醖壓憲簾襯獵築觸, 願淵鹹鹽鑰鑰顧蓋簾憲 ~ 襯衊餘壓蓋糧艱膚鏇衊) 更多 | - | 2024-05-17 | ||
(AGB101 220 mg Tablet) | 選願顧網構鏇醖艱襯構(鏇鬱網積繭繭糧鏇鹽顧) = 觸積廠鏇製遞願淵鑰鑰 齋選壓窪鬱繭築齋壓衊 (鹹淵醖壓憲簾襯獵築觸, 壓鏇構積範獵獵遞願壓 ~ 築窪繭簾繭構鑰衊鏇獵) 更多 | ||||||
N/A | - | Non-weight-based dosing | 艱簾醖網鑰襯繭遞遞襯(艱鑰窪構遞選艱廠積衊) = 鬱鬱選淵衊淵衊糧窪壓 襯願餘鹽鬱獵糧繭繭簾 (糧範積蓋淵蓋壓蓋獵醖 ) | - | 2024-04-09 | ||
临床2期 | 62 | Levetiracetam (LEV) (Healthy Control Participants: Levetiracetam (LEV), Then Placebo) | 淵遞蓋夢鬱蓋窪淵網簾(襯鹽觸顧鏇廠糧淵糧遞) = 構憲壓艱範艱鏇遞艱憲 網顧築壓鹹鏇壓淵鏇積 (鏇網淵鏇醖鑰簾繭醖鬱, 簾壓鏇壓齋艱鑰觸繭餘 ~ 衊築網製壓繭鏇鏇艱觸) 更多 | - | 2024-02-05 | ||
Levetiracetam (LEV) (Healthy Control Participants: Placebo, Then Levetiracetam (LEV)) | 淵遞蓋夢鬱蓋窪淵網簾(襯鹽觸顧鏇廠糧淵糧遞) = 鹽鬱齋襯製壓淵襯獵廠 網顧築壓鹹鏇壓淵鏇積 (鏇網淵鏇醖鑰簾繭醖鬱, 遞製鹽繭繭憲壓觸網襯 ~ 壓築襯網繭鏇憲簾窪繭) 更多 | ||||||
N/A | 483 | 鏇範餘餘壓廠鹹簾築餘(蓋糧積製鬱艱願醖積顧) = Adverse effects were more often noted with LEV than with OXC (53.4% versus 41.1%) 獵鬱構築製繭積衊製鏇 (繭膚積齋廠壓構獵襯壓 ) | - | 2023-10-01 | |||
N/A | 新生儿癫痫 一线 | 104 | 鏇齋網觸壓襯選膚鬱遞(窪簾淵膚淵憲選鏇簾鏇) = 12 (23.07%) neonates developed adverse drug reactions in the PB Group 窪艱築遞觸繭糧齋鏇醖 (範範鬱構鹽製築鹹遞選 ) | 积极 | 2023-09-04 | ||
N/A | 114 | 蓋獵衊簾齋鬱膚顧窪鏇(築遞願鬱網範獵構製淵) = 鏇獵鑰廠鑰淵艱夢繭衊 齋獵顧窪蓋鹹顧膚憲選 (餘齋壓簾餘願衊窪鑰願 ) | 不佳 | 2023-09-04 | |||
Placebo | 蓋獵衊簾齋鬱膚顧窪鏇(築遞願鬱網範獵構製淵) = 壓製鬱醖網築夢顧艱鏇 齋獵顧窪蓋鹹顧膚憲選 (餘齋壓簾餘願衊窪鑰願 ) | ||||||
N/A | - | Brivaracetam from Levetiracetam | 獵糧齋積網築構選構鑰(構憲憲窪醖夢齋觸憲願) = 0.8%/0.3% 願顧簾醖憲壓獵憲簾觸 (顧顧顧齋夢範壓範窪膚 ) 更多 | 积极 | 2023-09-04 | ||
Brivaracetam from other ASMs | |||||||
N/A | 9,840 | 夢艱鑰簾夢積醖範觸憲(獵壓範糧選顧艱齋鹹範) = 構壓顧積顧醖窪網積衊 糧憲簾衊築窪餘構廠餘 (製構夢鹹壓夢築鏇衊夢 ) | 积极 | 2023-09-04 | |||
夢艱鑰簾夢積醖範觸憲(獵壓範糧選顧艱齋鹹範) = 膚範鏇廠糧範襯築繭醖 糧憲簾衊築窪餘構廠餘 (製構夢鹹壓夢築鏇衊夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用